• Devesa, S.S. & Fears, T. (1992) Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Research, 52(Suppl. 19), 5432s5440s.
  • Gisselbrecht, C., Gaulard, P., Lepage, E., Coifier, B., Briere, J., Haioun, C., Cazals-Hatem, D., Bosly, A., Xerri, L., Tilly, H., Berger, F., Bouhaabdallah, R. & Diebold, J. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood, 92, 7682.
  • Krug, L.M., Ng, K.K., Kris, M.G., Miller, V.A., Tong, W., Heelan, R.T., Leon, L., Kelly, J., Grant, S.C. & Sirotnak, F.M. (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clinical Cancer Research, 6, 34933498.
  • Krug, L.M., Azzoli, C.G., Kris, M.G., Miller, V.A., Khokhar, N.Z., Tong, W., Ginsberg, M.S., Venkatraman, E., Tyson, L., Pizzo, B., Baez, V., Ng, K.K. & Sirotnak, F.M. (2003) 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clinical Cancer Ressearch, 9, 20722078.
  • Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. & Linet, M.S. (2005) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood, 107, 265276.
  • O'Connor, O.A. (2005) Developing new drugs for the treatment of lymphoma. European Journal of Haematology Supplementum, 75(Suppl. 66), 150158.
  • Rudiger, T., Weisenburger, D.D., Anderson, J.R., Arimitage, J.O., Diebold, J., MacLennan, K.A., Nathwani, B.N., Ullrich, F. & Muller-Hermelink, H.K. Non-hodgkin's Lymphoma Classificatio Project. (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology, 13, 140149.
  • Sirotnak, F.M., DeGraw, J.I., Schmid, F.A., Goutas, L.J. & Moccio, D.M. (1984a) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemotherapy and Pharmacology, 12, 2630.
  • Sirotnak, F.M., DeGraw, J.I., Moccio, D.M., Samuels, L.L. & Goutas, L.J. (1984b) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemotherapy and Pharmacology, 12, 1825.
  • Sirotnak, F.M., DeGraw, J.I., Colwell, W.T. & Piper, J.R. (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemotherapy and Pharmacology, 42, 313318.
  • Toner, L., Vrhovac, R., Smith, E., Gardner, J., Heaney, M., Teruya-Feldstein, J., Sirotnak, F. & O'Connor, O.A. (2006) The schedule dependent effects of the novel antifolate 10-propargyl-10dezaminopterin (PDX) and gemcitabine are markedly superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clinical Cancer Research, 123, 924932.
  • Wang, E.S., O'Connor, O.A., Zelenetz, A. & Moore, M. (2003) Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leukemia and Lymphoma, 44, 10271035.